Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5919_Библиотеки_им_академика_М_И_Перельмана.pdf
Drug Delivery to the Gastrointestinal Tract: Challenges and Opportunities 299
facilitating the transport of drugs across the barrier. These enhancers can disrupt tight junctions or inhibit efflux transporters,
improving drug absorption.
6.5 Tight Junction Modulators
6.6 Development of Prodrugs
6.7 Efflux
Transporter Inhibitors
Tight junction modulators are substances capable of temporarily
opening the tight junctions between epithelial cells, thereby
enhancing paracellular permeability. Examples of these modulators
include chitosan, zonula occludens toxin, and specific peptides.
Through their action in disrupting tight junctions, these compounds facilitate improved absorption of large molecules and
drugs that typically have low permeability. This mechanism is
instrumental in enhancing the bioavailability of such substances.
Prodrugs are inactive compounds that are converted to active drugs
in the body through metabolic processes. By designing prodrugs
that are specifically activated in the GI tract, it is possible to enhance
drug absorption and target specific regions of the GI tract. For
example, prodrugs that are activated by enzymes present in the
colon can be used to deliver drugs specifically to the large intestine.
Efflux transporters, such as P-glycoprotein, function to restrict
drug absorption by actively transporting drugs back into the gastrointestinal lumen. Inhibitors of these transporters play a cr ucial
role in enhancing drug absorption by reducing this efflux mechanism. Examples of efflux transporter inhibitors include verapamil,
cyclosporine A, and specific flavonoids. Through inhibition of
efflux transporters, these compounds effectively enhance the bioavailability of drugs that are substrates for these transporters,
thereby optimizing therapeutic outcomes.
7 Conclusion
In conclusion, while drug delivery to the gastrointestinal tract
presents for midable obstacles due to its intricate environment and
physiological dynamics, the field also holds immense promise for
innovative solutions. Advances in formulation techniques, controlled release systems, and targeted delivery strategies offer compelling avenues to overcome these challenges. Technologies such as
nanoparticle-based systems, osmotic pumps, and mucoadhesive
formulations demonstrate the potential to enhance drug stability,
improve absorption, and prolong therapeutic effect. Furthermore,
the integration of absorption enhancers and targeted delivery systems holds the key to achieving precise drug delivery and maximizing therapeutic efficacy while minimizing adverse effects. As
research progresses and our understanding of gastrointestinal physiology deepens, the future of GI drug delivery looks promising,
poised to usher in new standards of effectiveness and patient care in
pharmacotherapy.
300 Milindmitra K. Lonare et al.
References
1. Chu JN, Traverso G (2022) Foundations of
gastrointestinal-based drug delivery and future
developments. Nat Rev Gastroenterol Hepatol
19(4):219–238.
s41575-022-00496-8
2. Lou J, Duan H, Qin Q et al (2023) Advances in
oral drug delivery systems: challenges and
opportunities. Pharmaceutics 15(2):484.
h t t p s : / /doi.org/10.3390/
pharmaceutics15020484
3. Manallack DT (2007) The p K a distribution of
drugs: application to drug discovery. Perspect
Medicin Chem 1:25–38
4. Viswanathan P, Muralidaran Y, Ragavan G
(2017) Challenges in oral drug delivery: a
nano-based strategy to overcome. In: Nanostructures for oral medicine. Elsevier Inc, pp
173–201
5. Markovic M, Ben-Shabat S, Dahan A (2020)
Prodrugs for improved drug delivery: lessons
learned from recently developed and marketed
products. Pharmaceutics 12(11):1031.
h t t p s : / /doi.org/10.3390/
pharmaceutics12111031
6. Hua S (2020) Advances in oral drug delivery
for regional targeting in the gastrointestinal
tract – influence of physiological, pathophysiological and pharmaceutical factors. Front Pharmacol 11(April):1–22.
3389/fphar.2020.00417
7. Peng S, Yin J, Liu X, Jia B, Chang Z, Lu H,
Jiang N, Chen Q (2015 Aug) First insights into
the microbial diversity in the omasum and
reticulum of bovine using Illumina sequencing.
J Appl Genet 56(3):393–401
8. Garba AM, Firincioglu SY (2023) Role of
encapsulation nutrients for improvement of
ruminant performance and ruminant derived –
products. Eurasian J Agric Res 7(2):109–126
9. Contreras-Lo´pez G, Carrillo-Lo´pez LM, Vargas-Bello-Pe
Microencapsulation of feed additives with
potential in livestock and poultry production:
a systematic review. Chilean J Agric Anim Sci
):22
40(1
chjaas40-21mfgi40021
10. Wei W, Zhen Y, Wang Y, Shahzad K, Wang M
(2022) Advances of rumen functional bacteria
and the application of micro-encapsulation fermentation technology in ruminants: a review.
Fermentation 8(10):564.
3390/fermentation8100564
11. Belleza M (2023) Digestive system anatomy
and physiology. Nurseslabs, pp 1–33
9–249.
https://doi.org/10.1038/
https://doi.org/10.
´
rez E, Garcı´a-Galicia IA (2024)
https://doi.org/10.29393/
https://doi.org/10.
12. Smith ME, Morton DG (2010) Overview of
the digestive system. Dig Syst:1–18
13. Okumura R, Takeda K (2017) Roles of intestinal epithelial cells in the maintenance of gut
homeostasis. Exp Mol Med 49(5):e338
14. Wijngaarden MA, van der Zon GC, van Dijk
KW, Pijl H, Guigas B (2017) Regulation of
skeletal muscleenergy/nutrient-sensing pathways during metabolic adaptation to fasting in
healthy humans. Exp Mol Med 49(6):e358.
https://doi.org/10.1038/emm.2017.58
15. Zhou A, Yuan Y, Yang M, Huang Y, Li X, Li S
et al (2022) Crosstalk between the gut microbiota and epithelial cells under physiological
and infectious conditions. Front Cell Infect
Microbiol 12:1–11.
3389/fcimb.2022.818101
16. Shakweh M, Ponchel G, Fattal E (2004) Particle uptake by Peyer’s patches: a pathway for
drug and vaccine delivery. Expert Opin Drug
Deliv 1(1):141–163
17. Orlando LA, Orlando RC (2004) Esophagus,
Anatomy. In: Johnson LR (ed) Encyclopedia of
gastroenterology. Elsevier, New York, pp
763–766
18. Rao JN, Wang JY (2010) Regulation of gastrointestinal mucosal growth. In: Intestinal architecture and development. Morgan & Claypool
Life Sciences, San Rafael
19. Baliga S, Muglikar S, Kale R (2013)
Salivary pH: a diagnostic biomarker. J Indian
Soc Periodontol 17(4):461–465.
org/10.4103/0972-124X.118317
20. Fallingborg J (1999) Intraluminal pH of the
human gastrointestinal tract. Dan Med Bull
46(3):183–196
21. Xu Q, Qiao Q, Gao Y et al (2021) Gut microbiota and their role in health and metabolic
disease of dairy cow. Front Nutr 8:701511.
https://doi.org/10.3389/fnut.2021.701511
22. Reid JT, Sykee JF (1945) The influence of
ascorbic acid on the activity of gouadotropic
hormones in Guinea pigs. J Nutr 30:477–483
23. SchWarc C, Heri AN, B. (1924) Beitrage zur
Physiologie der Verdauung. Die
H-Ionenkonzcntration im Spcichel einiger
Haustiere. Pflugers Arch ges Physiol 202:
475–477
24. Wise GH, Miller PG, Anderson GW (1940)
Changes observed in Milk “Shamfed” to dairy
calves. J Dairy Sci 23:997–1011
25. Ricci S,
(2021) Supplementation with phytogenic
compounds modulates salivation and salivary
physico-chemical composition in cattle fed a
Rivera-Chacon R, Petri RM et al
https://doi.org/10.
https://doi.
Drug Delivery to the Gastrointestinal Tract: Challenges and Opportunities 301
high-concentrate diet. Front Physiol 12:
645529.
https://doi.org/10.3389/fphys.
2021.645529
26. Yan Y, Chen C, Chen Y, Wu Y, Shi Z (1998)
Arterial patterns in the thoracic and abdominal
segments of the esophagus: anatomy and clinical significance. Surg Radiol Anat 20(6):
399– 402.
https://doi.org/10.1007/
BF01653129
27. Geboes K, Geboes KP, Maleux G (2001) Vascular anatomy of the gastrointestinal tract. Best
Pract Res Clin Gastroenterol 15(1):1–14.
https://doi.org/10.1053/bega.2000.0152
28. Schmidt RE (2002) Age-related sympathetic
ganglionic neuropathology: human pathology
and animal models. Auton Neurosci 96:63–72
29. Phillips RJ, Powley TL (2007) Innervation of
the gastrointestinal tract: patterns of aging.
Auton Neurosci 136(1–2):1–19.
https://doi.
org/10.1016/j.autneu.2007.04.005
30. Furness JB, Costa M (1974) The adrenergic
innervation of the gastrointestinal tract. Ergeb
Physiol 69:2–51
31. Powley TL, Holst MC, Boyd DB, Kelly JB
(1994) Three-dimensional reconstructions of
autonomic projections to the gastrointestinal
tract. Microsc Res Tech 29:297–309
32. Lee YY, Erdogan A, Rao SS (2014) How to
assess regional and whole gut transit time with
wireless motility capsule. J Neurogastroenterol
Motil 20(2):265–270.
https://doi.org/10.
5056/jnm.2014.20.2.265
33. Azman M, Sabri AH, Anjani QK, Mustaffa MF,
Hamid KA (2022) Intestinal absorption study:
challenges and absorption enhancement strategies in improving oral drug delivery. Pharmaceuticals (Basel) 15(8):975.
https://doi.org/
10.3390/ph15080975
34. Thummel K (1996) Oral first pass elimination
of midazolam involves both gastrointestinal
and hepatic CYP3A-mediated metabolism.
Clin Pharmacol Ther 59:491–502
35. Meunier V (1995) The human intestinal epithelial cell line CaCo-2; pharmacological and
pharmacokinetic applications. Cell Biol Toxicol
11:187–194
36. Takeno S, Sakai T (1991) Involvement of the
intestinal microflora in nitrazepam-induced
teratogenicity in rats and its relationship to
nitroreduction. Teratology 44:209–214
37. Magnusson JO, Bergdahl B, Bogentoft C,
Jonsson UE (1982) Metabolism of digoxin
and absorption site. Br J Clin Pharmacol 14:
284–285
38. Vermes A, Kuijper EJ, Guchelaar HJ, Dankert J
(2003) An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora.
Chemotherapy 49:17–23
39. Sousa T, Paterson R, Moore V, Carlsson A,
Abrahamsson B, Basit AW (2008) The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 363:1–25
40. Delomenie C, Fouix S, Longuemaux S,
Brahimi N, Bizet C, Picard B, Denamur E,
Dupret JM (2001) Identification and functional characterization of arylamine
N-acetyltransferases in eubacteria: evidence
for highly selective acetylation of
5-aminosalicylic acid. J Bacteriol 183:3417–
3427
41. Xie Y, Hu F, Xiang D, Lu H, Li W, Zhao A,
Huang L, Wang R (2020) The metabolic effect
of gut microbiota on drugs. Drug Metab Rev
52(1):139–156.
https://doi.org/10.1080/
03602532.2020.1718691
42. Gavhane YN,
Yadav AV (2012) Loss of orally
administered drugs in GI tract. Saudi Pharm J
20(4):331–344.
https://doi.org/10.1016/j.
jsps.2012.03.005
Chapter 14
Drug Delivery to the Respiratory System: Novel Approaches
and Therapeutics
Pabbathi Shivakumar, Ramya Boinepally, and Matukumalli Usha Rani
Abstract
Respiratory drug delivery systems present a promising approach for the treatment of various pulmonary
diseases by directly targeting medications to the lungs. However, the development of effective respiratory
drug delivery systems encounters several challenges, including overcoming the lungs’ innate defense
mechanisms, achieving uniform drug distribution, and formulating stable and respirable drug particles.
This chapter examines the anatomy and physiology of the respiratory system, focusing on aspects relevant to
drug delivery, such as airflow dynamics, mucociliary clearance, and alveolar-capillary barrier function.
Traditional methods of respiratory drug delivery, including metered-dose inhalers, dry powder inhalers,
and nebulizers, are analyzed, elucidating their operational principles, advantages, and limitations. Recent
advancements in particle engineering, device design, and formulation strategies are also investigated, with
an emphasis on their potential to enhance the efficacy and precision of respiratory drug delivery. Novel
approaches, such as nanocarriers, smart inhalers, and targeted delivery systems, are explored as promising
avenues for addressing the challenges associated with respiratory drug delivery. Furthermore, the review
underscores the importance of understanding the lung microbiome and harnessing the respiratory immune
system for targeted drug delivery and immunomodulation. The integration of advanced imaging technologies, molecular biology, and computational modeling is anticipated to provide new insights into lung
structure and function, paving the way for the development of personalized and targeted respiratory
therapies.
Key words Respiratory drug delivery systems, Particle engineering, Nanocarriers, Smart inhalers,
Computational modeling, Personalized therapies
1 Introduction
The lungs, with their extensive surface area and vasculature, are an
optimal target for drug delivery in the treatment of respiratory
conditions, such as asthma, chronic obstructive pulmonary disease
(COPD), cystic fibrosis, and pulmonary infections. By directly
administering medications at the site of action, respiratory drug
delivery systems can achieve higher local drug concentrations at
303
304 Pabbathi Shivakumar et al.
reduced doses, potentially improving patient outcomes and minimizing the risk of adverse effects [
However, the development of efficacious respiratory drug
delivery systems remains challenging. The primary obstacle is overcoming the innate defense mechanisms of the respiratory tract,
which are designed to impede the entry of foreign particles.
These barriers include mucus layers, ciliary clearance, and complex
airway geometry, all of which can hinder the deposition and retention of therapeutic agents.
An additional significant challenge is achieving uniform drug
distribution throughout the lungs. The intricate branching structure of the airways and the heterogeneous nature of lung diseases
can result in uneven drug deposition, potentially leading to suboptimal treatment efficacy. Factors such as particle size, inhalation
technique, and device design play crucial roles in determining the
distribution and deposition patterns of inhaled medications.
Moreover, the formulation of drugs for respiratory delivery
presents a unique challenge. Ensuring the stability of active pharmaceutical ingredients, developing appropriate particle engineering
techniques, and designing delivery devices capable of generating
respirable aerosols with consistent and reproducible characteristics
are critical for successful respiratory drug delivery systems.
Recent advances in nanotechnology, particle engineering, and
device design have revealed new avenues for addressing these challenges. Innovative approaches, such as nanocarriers, smart inhalers,
and targeted delivery systems, are being investigated to enhance the
efficacy and precision of respiratory drug delivery.
1].
2 Anatomy and Physiology of the Respiratory System
It explains lung physiology by focusing on aspects relevant to drug
delivery, such as airflow dynamics, mucociliary clearance, and
alveolar-capillary barrier function. Understanding these factors is
crucial for developing effective drug delivery strategies [
respiratory system comprises a sophisticated network of organs and
tissues, facilitating gas exchange between the body and the environment. Their anatomical and physiological aspects are crucial for
understanding drug delivery mechanisms and developing efficacious therapeutic strategies. The respiratory system facilitates gas
exchange between the body and the environment and serves as a
potential route for drug delivery. Understanding its anatomy and
physiology is crucial for the development of effective therapeutic
strategies [
1. Upper Airways:
cavity, pharynx, and larynx, which filter, warm, and humidify
the incoming air. The nasal cavity is lined with ciliated
3].
The upper airways encompass the nose, nasal
2]. The
Drug Delivery to the Respiratory System: Novel Approaches and Therapeutics 305
epithelium and mucus-producing goblet cells that entrap particles and pathogens [
4]. Contemporary research has focused
on the role of nasal epithelial cells in innate immunity and their
potential as drug delivery targets.
2. Lower Airways: The lower airway includes the trachea, bronchi,
and bronchioles. The trachea bifurcates into two main bronchi,
which subsequently divide into smaller bronchioles [5]. This
branching pattern, termed the bronchial tree, augments the
surface area for gas exchange. Recent investigations have elucidated the significance of bronchial smooth muscle in regulating airflow and its role in pathologies such as asthma [
6].
3. Alveoli: The alveoli serve as the primary sites of gas exchange.
These microscopic air sacs are enveloped by a network of
capillaries, forming an alveolar-capillary interface. Recent
research has illuminated the complexity of alveolar epithelial
cells, including type I cells (for gas exchange) and type II cells
(for surfactant production) [
7]. Understanding alveolar struc-
ture and function is essential for developing inhaled medications and nanoparticle-based drug delivery systems.
4. Pulmonary Vasculature: Pulmonary circulation is characterized
by a low-pressure, high-flow system that facilitates gas
exchange [8]. Recent studies have emphasized the role of
pulmonary endothelial cells in maintaining vascular homeostasis and their potential as drug targets. The distinctive structure
of pulmonary capillaries, with their thin walls and extensive
surface area, renders them ideal for rapid drug absorption [
5. Airflow Dynamics: Airflow in
the respirator
y system is complex
9].
and varies throughout the respiratory cycle. Recent computational fluid dynamics studies have provided insights into airflow
patterns in different regions of the lungs [
10]. This knowledge
is crucial for optimizing inhaled drug delivery, particularly for
targeting specific pulmonary regions.
6. Mucociliary Clearance:
respiratory tract is lined with a
The
mucus layer and ciliated epithelium, which function synergistically to trap and remove particles. Recent studies have elucidated the importance of mucus composition and ciliary beat
frequency in the maintenance of this protective mechanism
[
11]. Understanding mucociliary clearance is essential for the
development of drugs that can overcome this barrier and reach
their intended targets.
7. Alveolar-Capillary Barrier
Function: The alveolar-capillary
barrier regulates the exchange of gases and substances between
the alveolar space and blood. Recent studies have focused on
the role of tight junctions and transport proteins in the maintenance of this barrier [
12]. Understanding the mechanism of
306 Pabbathi Shivakumar et al.
transepithelial transport is crucial for the development of drugs
that can effectively overcome this barrier.
8. Lung Microbiome: Recent studies have highlighted the significance of the lung microbiome in respiratory health and disease.
The composition of the lung microbiome can influence drug
metabolism and efficacy, making it an important consideration
in drug delivery.
9. Respiratory Immune System: The lungs possess a sophisticated
immune system that includes alveolar macrophages, dendritic
cells, and lymphoid tissues [
on harnessing immune components for targeted drug delivery
and immunomodulation.
A comprehensive understanding of respirator y anatomy and
physiology is indispensable for the development of effective drug
delivery strategies. Recent advancements in imaging technologies,
molecular biology, and computational modeling have provided
novel insights into lung structure and function, thereby creating
new possibilities for targeted and personalized respiratory
therapies.
13]. Recent studies have focused
3 Traditional Methods of Respiratory Drug Delivery
Inhalation devices, such as metered-dose inhalers (MDIs), dry
powder inhalers (DPIs), and nebulizers, are traditional methods
of pulmonary drug delivery [14]. Traditional respiratory drug
delivery methods encompass three primary types of inhalation
devices: metered-dose inhalers (MDIs), dry powder inhalers
(DPIs), and nebulizers. Each device exhibits distinct operational
principles, advantages, and limitations.
3.1 Metered-Dose Inhalers (MDIs)
MDIs consist of a pressurized canister containing the drug in
solution or suspension, along with propellants. Upon activation,
the device dispenses a precise dose of medication in aerosol form.
Pressurized metered-dose
advantages, including portability and compactness, rapid drug
delivery, consistent dose administration, and compatibility with a
wide range of medications [
15]. These features make pMDIs a
popular choice for delivery of respiratory medications. However,
they also have limitations that must be considered. Users must
coordinate actuation with inhalation, which can be challenging
for some patients [
16].
There is potential for oropharyngeal deposition, reducing the amount of medication reaching the lungs. The
cold-Freon effect may cause throat irritation in some patients. In
addition, environmental concerns have been raised regarding the
propellants used in pMDIs. Despite these limitations, pMDIs
inhalers (pMDIs) offer several
Drug Delivery to the Respiratory System: Novel Approaches and Therapeutics 307
remain a widely used and effective method for the delivery of
inhaled medications.
3.2 Dry Powder Inhalers (DPIs)
3.3 Nebulizers
Dry powder inhalers (DPIs) administer medication in powdered
form, utilizing the patient’s inhalation to generate aerosols and
disperse the powder into respirable particles [
17]. These devices
present several advantages: they are breath-activated, thereby mitigating coordination challenges; they are propellant-free; they provide stable for mulations; and they generally offer enhanced userfriendliness compared with metered dose inhalers (MDIs)
18]. However, DPIs also possess certain limitations, including
[
the necessity for sufficient inspiratory flow, susceptibility of powder
formulations to moisture, and potential variability in dosage delivery based on the patient’s inspiratory effort [
19] (Fig. 1).
These are medical devices that transform liquid medication into a
fine mist for inhalation by utilizing compressed air, ultrasonic
waves, or a vibrating mesh [
20]. These apparatuses offer several
advantages, including their suitability for patients with reduced
inspiratory flow, capacity to administer substantial medication
doses, applicability for pharmaceuticals not available in alternative
inhaler formats, and minimal requirements for patient coordination
21]. However, nebulizers have certain limitations. They are com-
[
paratively bulky and less portable than other inhalation devices,
Fig. 1 Schematic illustration showing particle deposition pattern
308 Pabbathi Shivakumar et al.
necessitate time-consuming treatment sessions, present a risk of
contamination if not properly maintained, and may result in potential medication waste [22]. Notwithstanding these drawbacks,
nebulizers remain a significant option for the administration of
respiratory medications, particularly in patients who may experience difficulties with other inhaler types.
Drug deposition in the lungs is influenced by several factors,
including particle size, inhalation technique, device characteristics,
and patient-specific variables [23]. Optimal lung deposition is generally achieved with particle sizes ranging from 1 to 5 μm, while
particles exceeding 5 μm tend to deposit in the upper airways, and
those smaller than 1 μm may be exhaled. Effective drug delivery is
contingent upon proper inhalation techniques, which encompasses
slow, deep inhalation followed by breath-holding, correct device
usage and positioning, as well as comprehensive patient education
and training [
aerosol generation mechanism, dose consistency, and ease of use
and maintenance, also significantly impact drug deposition. Furthermore, patient-specific factors, including lung anatomy, disease
state, inspiratory flow rate, age, and cognitive abilities, contribute
to variability in drug deposition within the lungs.
Traditional methods of pulmonary drug delivery encounter
numerous challenges that researchers and healthcare professionals
are actively addressing. These challenges include enhancing lung
deposition efficiency; improving patient adherence and technique;
developing formulations for a wider range of medications; addressing the specific needs of diverse patient populations (e.g., pediatric, elderly); optimizing the balance between efficacy, safety, and
cost-effectiveness; and integrating advanced technologies for
improved monitoring and adherence [
obstacles is essential for advancing the field of inhaled therapeutics
and improving patient outcomes across a spectrum of respiratory
conditions.
Novel drug delivery systems for the respiratory system have
emerged as promising approaches to address the limitations of
traditional methods. These innovative systems offer numerous
advantages that significantly enhance therapeutic efficacy and
patient outcomes.
24]. The characteristics of the delivery device, such as
25, 26]. Overcoming these
3.4 Enhanced Drug
Deposition Efficiency
Advanced delivery systems utilize sophisticated technologies to
optimize particle size, shape, and aerodynamic proper ties, resulting
in more precise and efficient drug deposition in the lungs [27]. This
improved efficiency ensures that a higher percentage of the administered dose reaches the intended target sites, potentially reducing
the required dosage and minimizing waste.